Mechanistically, SLC9A2 suppresses the EMT pathway and subsequent metastasis by inhibiting STAT3Y705 while also reducing tumor cell secretion of VEGFA, thus limiting tumor angiogenesis. The gene discussed is SLC9A2; the disease is neoplasm.